摘要
目的:探讨口服重组水蛭素的抗凝、抗血栓的作用。方法:将24只Beagle犬,随机分为水蛭素大、中、小剂量组剂量分别为(600,300,150AUT/kg)和空白对照组,每组6只。各试验组动物均经口给药,分别于给药前、达稳态前和达稳态后取血1～4mL,测定凝血时间(CT)、血浆凝血酶原时间(PT)、凝血酶凝固时间(TT)、纤维蛋白原(FBG)、活化部分凝血活酶时间(APTT);同时采用下腔静脉结扎法制作血栓模型,计算深静脉血栓形成百分率和血栓重量。结果:各用药组CT,PT,TT,APTT值与空白对照组均有差异或显著差异(P<0.05或P<0.01),给药对FBG没有明显影响;深静脉血栓形成百分率和血栓重量也有差异或显著差异。结论:口服重组水蛭素具有很强的特异性凝血酶抑制作用,同时具有抗凝、抗血栓作用,可用于防治实验性深静脉血栓形成。
Objective:To explore the effect of oral recombinant hirudin on anticoagulant and antithrombotic function.Methods:Inferior vena cava thrombosis in Beagle dog and CT(coagulation time),PT(prothrombin time),TT(thrombin time),APTT(activated partial thromboplastin time),FBG(fibrinogen)were used to study oral recombinant hirudin's anticoagulant and antithrombotic effects.Results:Oral recombinant hirudin obviously lengthen CT,PT,TT,APTT,have no effect on FBG.Oral recombinant hirudin can reduce dry and wet weight of thrombosis in vitro.The anticoagulant and antithrombotic activity of oral recombinant hirudin was different from that of placebo group significantly in statistics.Conclusion:Our results show that oral recombinant hirudin have good anticoagulant and antithrombotic functions.
出处
《中国药业》
CAS
2005年第6期30-31,共2页
China Pharmaceuticals
关键词
重组水蛭素
抗凝
抗血栓
犬
recombinant hirudin:anticoagulant:antithrombotic:thrombosis
